共 50 条
- [1] Results of a phase I trial combining ridaforolimus (mTOR inhibitor) and MK-0752 (Notch inhibitor) in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Piha-Paul, Sarina AnneMunster, Pamela N.Hollehecque, AntoineArgiles, GuillemDajanl, OlavCheng, Jonathan D.Wang, RuixueSwift, Ann M.Tosolini, AlessandraGupta, Shilpa
- [2] Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid TumorsJOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (19) : 2307 - 2313Krop, IanDemuth, TimGuthrie, TinaWen, Patrick Y.Mason, Warren P.Chinnaiyan, PrakashButowski, NicholasGroves, Morris D.Kesari, SantoshFreedman, Steven J.Blackman, SamuelWatters, JamesLoboda, AndreyPodtelezhnikov, AlexeiLunceford, JaredChen, CongGiannotti, MaxineHing, JeremyBeckman, RobertLoRusso, Patricia
- [3] Phase I study of the Gamma Secretase Inhibitor MK-0752 in patients with metastatic breast and other advanced solid tumorsCANCER RESEARCH, 2009, 69LoRusso, PatriciaDemuth, TimHeath, ElisabethMalburg, LisaPilat, Mary JoKesari, SantoshRussak, JasonKnowles, JamesBeckman, RobertFang, LanyanStone, JulieKrop, Ian
- [4] Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumoursEUROPEAN JOURNAL OF CANCER, 2015, 51 (14) : 1865 - 1873Piha-Paul, S. A.Munster, P. N.Hollebecque, A.Argiles, G.Dajani, O.Cheng, J. D.Wang, R.Swift, A.Tosolini, A.Gupta, S.
- [5] A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinomaBritish Journal of Cancer, 2018, 118 : 793 - 801Natalie CookBristi BasuDonna-Michelle SmithAarthi GopinathanJeffry EvansWilliam P StewardDaniel PalmerDavid PropperBalaji VenugopalMirela HateganD Alan AnthoneyLisa V HampsonMichael NebozhynDavid TuvesonHayley Farmer-HallHelen TurnerRobert McLeodSarah HalfordDuncan Jodrell
- [6] A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinomaBRITISH JOURNAL OF CANCER, 2018, 118 (06) : 793 - 801Cook, NatalieBasu, BristiSmith, Donna-MichelleGopinathan, AarthiEvans, JeffrySteward, William P.Palmer, DanielPropper, DavidVenugopal, BalajiHategan, MirelaAnthoney, D. AlanHampson, Lisa V.Nebozhyn, MichaelTuveson, DavidFarmer-Hall, HayleyTurner, HelenMcLeod, RobertHalford, SarahJodrell, Duncan
- [7] Phase lb Trial of the Gamma Secretase Inhibitor (GSI), MK-0752 Followed by Docetaxel in Locally Advanced or Metastatic Breast CancerCANCER RESEARCH, 2010, 70Schott, A. F.Chang, J. C.Krop, I. E.Griffith, K. A.Layman, R. M.Hayes, D. F.Wicha, M. S.
- [8] A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias.JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 357S - 357SDeangelo, D. J.Stone, R. M.Silverman, L. B.Stock, W.Attar, E. C.Fearen, I.Dallob, A.Matthews, C.Stone, J.Freedman, S. J.Aster, J.
- [9] A phase I trial of the γ-secretase inhibitor (GSI) MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (PDAC).JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Cook, NatalieBasu, BristiSmith, Donna-MichelleGopinathan, AarthiEvans, Thomas JeffSteward, William P.Hagemann, ThorstenVenugopal, BalajiTuveson, David A.Hategan, MirelaAnthoney, David AlanFarmer, HayleyTurner, HelenMcLeod, RobertHalford, Sarah E. R.Jodrell, Duncan Ian
- [10] A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumoursBRITISH JOURNAL OF CANCER, 2014, 111 (10) : 1932 - 1944Brana, I.Berger, R.Golan, T.Haluska, P.Edenfield, J.Fiorica, J.Stephenson, J.Martin, L. P.Westin, S.Hanjani, P.Jones, M. B.Almhanna, K.Wenham, R. M.Sullivan, D. M.Dalton, W. S.Gunchenko, A.Cheng, J. D.Siu, L. L.Gray, J. E.